These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7037038)

  • 21. Pharmacological treatment of Raynaud's phenomenon with special reference to calcium-entry blockers.
    Nilsson H
    Acta Pharmacol Toxicol (Copenh); 1986; 58 Suppl 2():137-49. PubMed ID: 2872769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon.
    Bunker CB; Reavley C; O'Shaughnessy DJ; Dowd PM
    Lancet; 1993 Jul; 342(8863):80-3. PubMed ID: 8100913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease--a rebound phenomenon?
    Sinzinger H; Silberbauer K; Horsch AK; Gall A
    Prostaglandins; 1981 Jan; 21(1):49-51. PubMed ID: 7010457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possibilities for clinical use of prostacyclin in vascular disease.
    Poredos P
    Pflugers Arch; 2000; 440(5 Suppl):R137-8. PubMed ID: 11005643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The response of skin perfusion and of rheological and immunological variables to intravenous prostanoid administration in Raynaud's phenomenon secondary to collagenosis.
    Drinda S; Neumann T; Pöhlmann G; Vogelsang H; Stein G; Wolf G; Hein G
    Vasa; 2005 Nov; 34(4):243-9. PubMed ID: 16363279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of Raynaud's phenomenon].
    Lazareth I
    Ann Dermatol Venereol; 1987; 114(8):1035-8. PubMed ID: 2892456
    [No Abstract]   [Full Text] [Related]  

  • 27. Prostaglandin E1 vasospastic disease and thermography.
    Kyle V; Parr G; Salisbury R; Thomas PP; Hazleman B
    Ann Rheum Dis; 1985 Feb; 44(2):73-8. PubMed ID: 3977414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epoprostenol and severe arterial disease.
    Olsson AG
    Lancet; 1983 Mar; 1(8326 Pt 1):711-2. PubMed ID: 6132070
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacotherapy of Raynaud's phenomenon.
    Belch JJ; Ho M
    Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.
    Torley HI; Madhok R; Capell HA; Brouwer RM; Maddison PJ; Black CM; Englert H; Dormandy JA; Watson HR
    Ann Rheum Dis; 1991 Nov; 50(11):800-4. PubMed ID: 1722967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New lines in therapy of Raynaud's phenomenon.
    Lambova SN; Müller-Ladner U
    Rheumatol Int; 2009 Feb; 29(4):355-63. PubMed ID: 19037602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemodynamic effects of intravenous prostacyclin in stable angina pectoris.
    Firth BG; Winniford MD; Campbell WB; Hillis LD
    Am J Cardiol; 1983 Sep; 52(5):439-43. PubMed ID: 6351580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of prostacyclin on cerebral vasospasm. An experimental study.
    Quintana L; Konda R; Ishibashi Y; Yoshimoto T; Suzuki J
    Acta Neurochir (Wien); 1982; 62(3-4):187-93. PubMed ID: 7048862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon.
    Kyle MV; Belcher G; Hazleman BL
    J Rheumatol; 1992 Sep; 19(9):1403-6. PubMed ID: 1279169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective suprasensitivity to calcitonin-gene-related peptide in the hands in Raynaud's phenomenon.
    Shawket S; Dickerson C; Hazleman B; Brown MJ
    Lancet; 1989 Dec; 2(8676):1354-7. PubMed ID: 2574303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of intravenous prostacyclin on resting pains and healing of ischaemic ulcers in peripheral artery disease.
    Olsson AG; Nilsson E
    Prostaglandins Med; 1981 Apr; 6(4):329-39. PubMed ID: 7025066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial.
    Belch JJ; McKay A; McArdle B; Leiberman P; Pollock JG; Lowe GD; Forbes CD; Prentice CR
    Lancet; 1983 Feb; 1(8320):315-7. PubMed ID: 6130330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of Raynaud's phenomenon].
    Levy Y; Shoenfeld Y
    Harefuah; 1993 Mar; 124(5):288-91. PubMed ID: 8098699
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of severe Raynaud syndrome in scleroderma or thromboangiitis obliterans with prostacyclin (prostaglandin I2)].
    Rüthlein HJ; Riegger G; Auer IO
    Z Rheumatol; 1991; 50(1):16-20. PubMed ID: 2058317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostaglandin E-1 and peripheral vascular disease.
    Kyle V; Hazleman B
    Lancet; 1983 Jul; 2(8344):282. PubMed ID: 6135105
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.